ScoreWhy is Emcure Pharmaceuticals Ltd ?
1
High Management Efficiency with a high ROCE of 21.82%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.84 times
3
Healthy long term growth as Net Sales has grown by an annual rate of 15.40% and Operating profit at 16.32%
4
Positive results in Jun 26
- ROCE(HY) Highest at 22.47%
- NET SALES(Q) Highest at Rs 2,580.45 cr
- OPERATING PROFIT TO INTEREST(Q) Highest at 16.88 times
5
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 3.89% over the previous quarter and collectively hold 13.34% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
6
Market Beating Performance
- The stock has generated a return of 41.34% in the last 1 year, much higher than market (BSE500) returns of 4.11%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Emcure Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Emcure Pharma for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Emcure Pharma
41.34%
1.28
32.27%
Sensex
-2.63%
-0.19
13.57%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
18.32%
EBIT Growth (5y)
29.20%
EBIT to Interest (avg)
7.47
Debt to EBITDA (avg)
1.01
Net Debt to Equity (avg)
0.28
Sales to Capital Employed (avg)
1.36
Tax Ratio
26.69%
Dividend Payout Ratio
8.34%
Pledged Shares
0.04%
Institutional Holding
13.34%
ROCE (avg)
20.38%
ROE (avg)
17.32%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
37
Price to Book Value
7.60
EV to EBIT
25.08
EV to EBITDA
19.70
EV to Capital Employed
6.13
EV to Sales
4.03
PEG Ratio
0.99
Dividend Yield
0.15%
ROCE (Latest)
22.79%
ROE (Latest)
19.15%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
ROCE(HY)
Highest at 22.47%
NET SALES(Q)
Highest at Rs 2,580.45 cr
OPERATING PROFIT TO INTEREST(Q)
Highest at 16.88 times
PBDIT(Q)
Highest at Rs 532.50 cr.
PBT LESS OI(Q)
Highest at Rs 391.46 cr.
PAT(Q)
Highest at Rs 293.98 cr.
EPS(Q)
Highest at Rs 15.50
-1What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 147.52 cr
Loading Valuation Snapshot...
Here's what is working for Emcure Pharma
Net Sales - Quarterly
Highest at Rs 2,580.45 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Operating Profit to Interest - Quarterly
Highest at 16.88 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Operating Profit (PBDIT) - Quarterly
Highest at Rs 532.50 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 391.46 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 293.98 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 293.98 cr has Grown at 24.1% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 236.93 CrMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 15.50
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Emcure Pharma
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 147.52 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
